Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Hypertension Research
  • View all journals
  • Search
  • Log in
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. hypertension research
  3. review
  4. article
The Metabolic Syndrome as a Concept of Adipose Tissue Disease
Download PDF
Download PDF
  • Review
  • Published: 01 July 2008

The Metabolic Syndrome as a Concept of Adipose Tissue Disease

  • Eiji Oda1 

Hypertension Research volume 31, pages 1283–1291 (2008)Cite this article

  • 3045 Accesses

  • 3 Altmetric

  • Metrics details

Abstract

The metabolic syndrome is a constellation of interrelated metabolic risk factors that appear to directly promote the development of diabetes and cardiovascular disease. However, in 2005, the American Diabetes Association and the European Association for the Study of Diabetes jointly stated that no existing definition of the metabolic syndrome meets the criteria of a syndrome, and there have been endless debates on the pros and cons of using the concept of this syndrome. The controversy may stem from confusion between the syndrome and obesity. Obesity is an epidemic, essentially contagious disease caused by an environment of excess nutritional energy and reinforced by deeply rooted social norms. The epidemic of obesity should be prevented or controlled by social and political means, similar to the approaches now being taken to combat global warming. The diagnosis of metabolic syndrome is useless for this public purpose. The purpose of establishing criteria for diagnosing metabolic syndrome is to find individuals who are at increased risk of diabetes and cardiovascular disease and who require specific therapy including diet and exercise. The syndrome may be an adipose tissue disease different from obesity; in that case, it would be characterized by inflammation clinically detected through systemic inflammatory markers such as high-sensitivity Creactive protein and insulin resistance reflecting histological changes in adipose tissue. However, many problems in defining the optimal diagnostic criteria remain unresolved.

Similar content being viewed by others

Metabolic syndrome

Article 17 October 2024

Programming of metabolism by adipokines during development

Article 13 April 2023

Cardiometabolic syndrome and associated factors among Ethiopian public servants, Addis Ababa, Ethiopia

Article Open access 19 October 2021

Article PDF

References

  1. Reaven GM : Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.

    Article  CAS  PubMed  Google Scholar 

  2. DeFronzo RA, Ferrannini E : Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–194.

    CAS  PubMed  Google Scholar 

  3. Kaplan NM : The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514–1520.

    CAS  PubMed  Google Scholar 

  4. Lemieux I, Pascot A, Couillard C, et al: Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179–184.

    CAS  PubMed  Google Scholar 

  5. Ridker PM, Wilson PW, Grundy SM : Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818–2825.

    CAS  PubMed  Google Scholar 

  6. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R : Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448–1454.

    PubMed  Google Scholar 

  7. Iso H, Kobayashi M, Ishihara J, et al: Intake of fish and n-3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-based (JPHC) Study Cohort 1. Circulation 2006; 113: 195–202.

    CAS  PubMed  Google Scholar 

  8. Ouellet V, Marois J, Weisnagel SJ, Jacques H : Dietary cod otein improves insulin sensitivity in insulin-resistant men and women. Diabetes Care 2007; 30: 2816–2821.

    CAS  PubMed  Google Scholar 

  9. Riserus U, Arnlov J, Berglund L : Long-term predictors of insuli resistance. Role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 2007; 30: 2928–2933.

    PubMed  Google Scholar 

  10. Oh SW, Yoon YS, Lee ES, et al: Association between cigarette smoking and metabolic syndrome: the Korea National Health and Nutrition Examination Survey. Diabetes Care 2005; 28: 2064–2066.

    PubMed  Google Scholar 

  11. Gustat J, Srinivasan SR, Elkasabany A, Berenson GS : Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: the Bogalusa Heart Study. J Clin Epidemiol 2002; 55: 997–1006.

    PubMed  Google Scholar 

  12. Ford ES, Giles WH, Dietz WH : Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.

    Article  PubMed  Google Scholar 

  13. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE : Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 90: 1929–1935.

    PubMed  Google Scholar 

  14. Lee D, Lee I, Jin S, Steffes M, Jacobs DR Jr : Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2007; 30: 622–628.

    CAS  PubMed  Google Scholar 

  15. Ruderman NB, Schneider SH, Berchtold P : The “metabolically- obese,” normal-weight individual. Am J Clin Nutr 1981; 34: 1617–1621.

    CAS  PubMed  Google Scholar 

  16. Nakamura T, Tokunaga K, Shimomura I, et al: Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994; 107: 239–246.

    CAS  PubMed  Google Scholar 

  17. Lamarche B, Tchernof A, Mauriege P, et al: Fasting insulinand apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955–1961.

    CAS  PubMed  Google Scholar 

  18. World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Geneva, World Health Organization, 1999.

  19. Balkau B, Charles MA : Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetes Med 1999; 16: 442–443.

    CAS  Google Scholar 

  20. Expert Panel on the Detection, Evaluation, and Treatmentof High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

  21. Einhorn D, Reaven GM, Cobin RH, et al: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237–252.

    PubMed  Google Scholar 

  22. Alverti KGMM, Zimmet P, Shaw J : Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.

    Google Scholar 

  23. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752.

    PubMed  Google Scholar 

  24. Kahn R, Buse J, Ferrannini E, Stern M : The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289–2304.

    PubMed  Google Scholar 

  25. Grundy SM : Does the metabolic syndrome exist? Diabetes Care 2006; 29: 1689–1692.

    PubMed  Google Scholar 

  26. Kahn R : The metabolic syndrome (emperor) wears no clothes. Diabetes Care 2006; 29: 1693–1696.

    Google Scholar 

  27. Reaven GM : The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006; 83: 1237–1247.

    CAS  PubMed  Google Scholar 

  28. Grundy SM : Does a diagnosis of metabolic syndrome have value in clinical practice. Am J Clin Nutr 2006; 83: 1248–1251.

    CAS  PubMed  Google Scholar 

  29. Ferrannini E : Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007; 92: 396–398.

    CAS  PubMed  Google Scholar 

  30. Grundy SM : Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92: 399–404.

    CAS  PubMed  Google Scholar 

  31. Kahn R : Metabolic syndrome. Is it a syndrome? Does it matter. Circulation 2007; 115: 1806–1811.

    PubMed  Google Scholar 

  32. Beaser RS, Levy P : Metabolic syndrome. A work in progress, but a useful construct. Circulation 2007; 115: 1812–1818.

    PubMed  Google Scholar 

  33. Sundstrom J, Vallhagen E, Riserus U, et al: Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006; 29: 1673–1674.

    PubMed  Google Scholar 

  34. Eckel RH, Kahn R, Robertson RM, Rizza RA : Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006; 113: 2943–2946.

    PubMed  Google Scholar 

  35. Malik S, Wong ND, Franklin SS, et al: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–1250.

    PubMed  Google Scholar 

  36. McNeil AM, Rosamond WD, Girman CJ, et al: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 385–390.

    Google Scholar 

  37. Ford ES : Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005; 28: 1769–1778.

    PubMed  Google Scholar 

  38. Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB : Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066–3072.

    CAS  PubMed  Google Scholar 

  39. The DECODE Study Group, Qiao Q : Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49: 2837–2846.

    Google Scholar 

  40. Gami AS, Witt BJ, Howard DE, et al: Metabolic syndrome and risk of incident cardiovascular events and death. J Am Coll Cardiol 2007; 49: 403–414.

    CAS  PubMed  Google Scholar 

  41. Ninomiya T, Kubo M, Doi Y, et al: Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population. The Hisayama Study. Stroke 2007; 38: 2063–2069.

    CAS  PubMed  Google Scholar 

  42. Sone H, Tanaka S, Ishibashi S, et al: The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions. Diabetes Care 2006; 29: 145–147.

    PubMed  Google Scholar 

  43. Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN : The importance of waist circumference in the definition of metabolic syndrome. Prospective analyses of mortality in men. Diabetes Care 2006; 29: 404–409.

    PubMed  Google Scholar 

  44. Chen H, Pan W : Probable blind spot in the International Diabetes Federation definition of metabolic syndrome. Obesity 2007; 15: 1096–1100.

    PubMed  Google Scholar 

  45. Yoon YS, Lee ES, Park C, Lee S, Oh SW : The new definition of metabolic syndrome by the International Diabetes Federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised National Cholesterol Education Program: the Korea NHANES Study. Int J Obes 2007; 31: 528–534.

    CAS  Google Scholar 

  46. Tong PC, Kong AP, So W, et al: The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1206–1211.

    PubMed  Google Scholar 

  47. Tanomsup S, Aekplakorn W, Sritara P, et al: A comparison of components of two definitions of the metabolic syndrome related to cardiovascular disease and all-cause mortality in a cohort study in Thailand. Diabetes Care 2007; 30: 2138–2140.

    PubMed  Google Scholar 

  48. Lorenzo C, Serrano-Rios M, Maritinez-Larrad MT, et al: Is waist circumference an essential component of the metabolic syndrome? Diabetes Care 2007; 30: 2141–2142.

    CAS  PubMed  Google Scholar 

  49. Klein S, Allison DB, Heymsfield SB, et al: Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for WeightManagement and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 2007; 30: 1647–1652.

    PubMed  Google Scholar 

  50. Oda E : Criteria for diagnosing the metabolic syndrome. Am J Clin Nutr 2006; 84: 1251–1252.

    CAS  PubMed  Google Scholar 

  51. Ogden CI, Carroll MD, Cutin LR, McDowell MA, Tabak CJ, Flegal KM : Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549–1555.

    CAS  PubMed  Google Scholar 

  52. Ministry of Health, Labour and Welfere, Japan: The National Health and Nutrition Survey in Japan, 2004. Tokyo, Daiichi Shuppan, 2004 ( in Japanese).

  53. Adabs KF, Schatzkin A, Harris TB, et al: Overweight, obesity, and mortality in a large prospective cohort of 50 to 71 years old. N Engl J Med 2006; 355: 763–778.

    Google Scholar 

  54. Chei CL, Iso H, Yamagishi K, Inoue M, Tsugane S, JPHC Study Group: Body mass index and weight change since 20 years of age and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based Study. Int J Obes (Lond) 2008; 32 1: 144–151.

    CAS  Google Scholar 

  55. Kissebah AH, Vydelingum N, Murray R, et al: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254–260.

    CAS  PubMed  Google Scholar 

  56. Despres J, Nadeau A, Tremblay A, et al: Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989; 38: 304–309.

    CAS  PubMed  Google Scholar 

  57. Pouliot MC, Despres J, Lemieux S, et al: Waist circumference and abdominal saggital diameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460–468.

    CAS  PubMed  Google Scholar 

  58. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB : Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005; 81: 555–563.

    CAS  PubMed  Google Scholar 

  59. Matsuzawa YM : Pathophysiology and molecular mechanism of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 1997; 13: 3–13.

    CAS  PubMed  Google Scholar 

  60. Fox CS, Massaro JM, Hoffmann U, et al: Abdominal visceral and subcutaneous adipose tissue compartments. Association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48.

    PubMed  Google Scholar 

  61. Pou KM, Massaro JM, Hoffmann U, et al: Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham Heart Study. Circulation 2007; 116: 1234–1241.

    CAS  PubMed  Google Scholar 

  62. Kelley DE, Goodpaster BH : Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 2001; 24: 933–941.

    CAS  PubMed  Google Scholar 

  63. Montani UP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG : Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular disease. Int J Obes Relat Metab Disord 2004; 28: 558–565.

    Google Scholar 

  64. Rasouli N, Molavi B, Elbein SC, Kern PA : Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab 2007; 9 ( 1): 1–10.

    CAS  PubMed  Google Scholar 

  65. Kotronen A, Yki-Jarvinen H : Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27–38.

    CAS  PubMed  Google Scholar 

  66. Hotamisligil GS, Shargill NS, Spiegelman BM : Adipose expression of tumor necrosis factor-α: direct role in obesitylinked insulin resistance. Science 1993; 259: 87–91.

    CAS  PubMed  Google Scholar 

  67. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM : Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–432.

    CAS  PubMed  Google Scholar 

  68. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K : cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophy Res Commun 1996; 221: 286–298.

    CAS  Google Scholar 

  69. Steppan CM, Bailey ST, Bhat S, et al: The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–312.

    CAS  PubMed  Google Scholar 

  70. Fukuhara A, Matsuda M, Nishizawa M, et al: Visfatin: a protein secreted by visceral fat that mimicks the effects of insulin. Science 2005; 307: 426–430.

    CAS  PubMed  Google Scholar 

  71. Takahashi K, Mizuarai S, Araki H, et al: Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 2003; 278: 46654–46660.

    CAS  PubMed  Google Scholar 

  72. Yang Q, Graham TE, Mody N, et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356–362.

    CAS  PubMed  Google Scholar 

  73. Xu A, Wang Y, Xu JY, et al: Adipocyte fatty acid binding protein a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405–413.

    CAS  PubMed  Google Scholar 

  74. Dandona P, Aljada A, Mohanty P, et al: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an antiinflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257–3265.

    CAS  PubMed  Google Scholar 

  75. Hotamisligil GS : Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2006; 54: S73–S78.

    Google Scholar 

  76. Semenkovich CF : Insulin resistance and atherosclerosis. J Clin Invest 2006; 116: 1813–1822.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Kim JY, Wall E, Laplante M, et al: Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117: 2621–2637.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Bains RK, Wells SE, Flavell DM, et al: Visceral obesity without insulin resistance in late-onset obesity rats. Endocrinology 2004; 145: 2666–2679.

    CAS  PubMed  Google Scholar 

  79. Cinti S, Mitchell G, Barbatelli G, et al: Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 2347–2355.

    CAS  PubMed  Google Scholar 

  80. Kanda H, Tateya S, Tamori Y, et al: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494–1505.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Kamei N, Tobe K, Suzuki R, et al: Overexpression of monocyte chemoattractant protein-1 in adipose tissue causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602–26614.

    CAS  PubMed  Google Scholar 

  82. Wellen KE, Fucho R, Gregor MF, et al: Coordinated regulation of nutrient and inflammatory response by STAMP2 is essential for metabolic homeostasis. Cell 2007; 129: 537–548.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Strissel KJ, Stancheva Z, Miyoshi H, et al: Adipocyte death,adipose tissue remodeling, and obesity complications. Diabetes 2007; 56: 2910–2918.

    CAS  PubMed  Google Scholar 

  84. Kolak M, Westerbacka J, Velagapudi VR, et al: Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56: 1960–1968.

    CAS  PubMed  Google Scholar 

  85. Han TS, Satter N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM : Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016–2021.

    CAS  PubMed  Google Scholar 

  86. Sattar N, Gaw A, Scherbakova O, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–419.

    CAS  PubMed  Google Scholar 

  87. Nakanishi S, Yamane K, Kamei N, et al: Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 2003; 26: 2754–2757.

    CAS  PubMed  Google Scholar 

  88. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PWF : C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380–385.

    CAS  PubMed  Google Scholar 

  89. Ridker PM, Cook N : Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955–1959.

    PubMed  Google Scholar 

  90. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R : Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690–693.

    CAS  PubMed  Google Scholar 

  91. Doi Y, Kiyohara Y, Kubo M, et al: Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population. Diabetes Care 2005; 28: 2497–2500.

    CAS  PubMed  Google Scholar 

  92. Dehghan A, van Hoek M, Sijbrand EJG, Stijnen T, Hofman A, Witteman JCM : Risk of type 2 diabetes attributable to Creactive protein and other risk factors. Diabetes Care 2007; 30: 2695–2699.

    CAS  PubMed  Google Scholar 

  93. Sabatine MS, Morrow DA, Jablonski KA, et al: Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115: 1528–1536.

    PubMed  Google Scholar 

  94. Shamsuzzaman ASM, Winnicki M, Wolk R, et al: Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109: 2181–2185.

    CAS  PubMed  Google Scholar 

  95. Matsushita K, Yatsuya H, Tamakoshi K, et al: Inverse association between adiponectin and C-reactive protein in substantially healthy Japanese men. Atherosclerosis 2006; 188: 184–189.

    CAS  PubMed  Google Scholar 

  96. Nakamura H, Ito H, Egami Y, et al: Waist circumference is the main determinant of elevated C-reactive protein in metabolic syndrome. Diabetes Res Clin Pract 2008; 79: 330–336.

    CAS  PubMed  Google Scholar 

  97. Komatsu M, Ohfusa H, Aizawa T, Hashizume K : Adiponectin inversely correlates with high-sensitivity C-reactive protein and triglycerides, but not with insulin sensitivity in apparently healthy Japanese men. Endocrine J 2007; 54: 553–558.

    CAS  Google Scholar 

  98. Yoneda M, Mawatari H, Fujita K, et al: High-sensitivity Creactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573–582.

    CAS  PubMed  Google Scholar 

  99. Oda E, Oohara K, Abe A, et al: The optimal cut-off point of C-reactive protein as an optional component of metabolic syndrome in Japan. Circ J 2006; 70: 384–388.

    CAS  PubMed  Google Scholar 

  100. Saijo Y, Yoshioka E, Fukui T, Kawaharada M, Kishii R : Metabolic syndrome, C-reactive protein and increased arterial stiffness in Japanese subjects. Hypertens Res 2006; 29: 589–596.

    CAS  PubMed  Google Scholar 

  101. Matsushita K, Yatsuya H, Tamakoshi K, et al: High-sensitivity C-reactive protein is quite low in Japanese men at high coronary risk. Circ J 2007; 71: 820–825.

    CAS  PubMed  Google Scholar 

  102. Itoh T, Mizuno Y, Harada E, Yoshimura M, Ogawa H, Yasue H : Coronary spasm is associated with chronic lowgrade inflammation. Circ J 2007; 71: 1074–1078.

    CAS  PubMed  Google Scholar 

  103. Christakis NA, Fowler JH : The spread of obesity in a large social network over 32 years. N Engl J Med 2007; 357: 370–379.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Check-up Center, Tachikawa Medical Center, Nagaoka, Japan

    Eiji Oda

Authors
  1. Eiji Oda
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Eiji Oda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oda, E. The Metabolic Syndrome as a Concept of Adipose Tissue Disease. Hypertens Res 31, 1283–1291 (2008). https://doi.org/10.1291/hypres.31.1283

Download citation

  • Received: 20 December 2007

  • Accepted: 24 March 2008

  • Issue date: 01 July 2008

  • DOI: https://doi.org/10.1291/hypres.31.1283

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • metabolic syndrome
  • obesity
  • diabetes
  • cardiovascular disease
  • inflammation

This article is cited by

  • Role of exercise on visceral adiposity after spinal cord injury: a cardiometabolic risk factor

    • Jacob A. Goldsmith
    • Areej N. Ennasr
    • Ashraf S. Gorgey

    European Journal of Applied Physiology (2021)

  • Efficacy of verum and sham acupoint catgut embedding for treatment of obesity: Study protocol for a randomized controlled trial

    • Yu-Mei Zhou
    • Bing Yan
    • Zhuo-Xin Yang

    Trials (2019)

  • Human serum RNase-L level is inversely associated with metabolic syndrome and age

    • Yi-Ting Wang
    • Ping-Huei Tseng
    • Wei-Shiung Yang

    Cardiovascular Diabetology (2017)

  • Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis

    • C Merlotti
    • V Ceriani
    • A E Pontiroli

    International Journal of Obesity (2017)

  • A link between adipogenesis and innate immunity: RNase-L promotes 3T3-L1 adipogenesis by destabilizing Pref-1 mRNA

    • Yi-Ting Wang
    • Hou-Hsien Chiang
    • Wei-Shiung Yang

    Cell Death & Disease (2016)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open Access Fees and Funding
  • Guide to Authors
  • About the Editors
  • Message from Editors
  • Call for Paper
  • Contact
  • About the Partner
  • For Advertisers
  • Subscribe
  • Showcase of Graphical Abstracts on Hypertension Research

Publish with us

  • For Authors & Referees
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Hypertension Research (Hypertens Res)

ISSN 1348-4214 (online)

ISSN 0916-9636 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited